黄体期给予促性腺激素释放激素激动剂对体外受精/卵胞浆内单精子注射周期妊娠结局的影响:系统评价与Meta分析
该系统评价与Meta分析检索截至2015年11月的多个数据库,纳入11项随机对照试验、共3406例患者和3280个IVF/ICSI周期,评估黄体期给予促性腺激素释放激素激动剂(GnRH-a)的疗效与安全性。结果显示,与未给予者相比,黄体期给予GnRH-a者的活产/持续妊娠率、临床妊娠率和多胎妊娠率均显著升高。
要点
- 黄体期给予GnRH-a可提高IVF/ICSI周期的活产/持续妊娠率、临床妊娠率和多胎妊娠率。
- 纳入11项随机对照试验,共3406例患者、3280个IVF/ICSI周期。
- 作者认为黄体期给予GnRH-a可能成为IVF/ICSI黄体期支持的理想选择。
核心结论
- 黄体期给予GnRH-a可提高所有IVF/ICSI周期的活产/持续妊娠率、临床妊娠率和多胎妊娠率,可能成为IVF/ICSI治疗中黄体期支持的理想选择。
研究设计与样本
- 系统评价与Meta分析,电子检索PubMed、EMBASE、Cochrane Library、WHO ICTRP、ClinicalTrials.gov、CNKI、CBM和万方数据库截至2015年11月发表的随机对照试验(RCT)。
- 由两名评价者独立筛选文献、提取数据并按Cochrane手册评估方法学质量,采用Stata 13.0进行Meta分析。
- 共纳入11项RCT,涉及3406例患者、3280个IVF/ICSI周期。
主要发现
- 与未给予黄体期GnRH-a者相比,给予者的活产/持续妊娠率显著升高(RR=1.29,95%CI:1.11-1.51)。
- 与未给予黄体期GnRH-a者相比,给予者的临床妊娠率显著升高(RR=1.24,95%CI:1.08-1.43)。
- 与未给予黄体期GnRH-a者相比,给予者的多胎妊娠率显著升高(RR=1.95,95%CI:1.21-3.14)。
临床怎么用
- 作者认为,黄体期给予GnRH-a可提高IVF/ICSI周期的活产/持续妊娠率、临床妊娠率和多胎妊娠率,可能成为黄体期支持的理想选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the potential efficacy and safety of gonadotropin-releasing hormone agonist(GnRH-a) administration in the luteal-phase on in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycles in assisted reproductive technology (ART). Methods: The relevant papers published before November 2015 were electronically searched in PubMed, EMBASE, Cochrane Library, WHO ICTRP, ClinicalTrials.gov, CNKI, CBM and WanFang database to collect randomized controlled trial (RCT) involving GnRH-a administration in the luteal-phase on IVF/ICSI cycles in ART. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data, and assessed methodological quality according to the Cochrane Handbook. Then, Meta-analysis was performed using Stata 13.0. Results: A total of 3 406 patients, 3 280 IVF/ICSI cycles from 11 RCT were subjected to Meta-analysis. All cycles presented statistically significantly higher rates of live birth/ongoing pregnancy (RR=1.29, 95%CI: 1.11-1.51), clinical pregnancy (RR=1.24, 95%CI:1.08-1.43) and multiple pregnancy (RR=1.95, 95%CI:1.21-3.14) in patients who received luteal-phase GnRH-a administration compared with those who did not. Conclusions: These findings demonstrate that the luteal-phase GnRH-a administration could increase birth/ongoing pregnancy rate, clinical pregnancy rate and multiple pregnancy rate in all cycles, so it may be an ideal choice for luteal phase support in patients undergoing IVF/ICSI therapy.
引用
- Yu LP, Liu N, Liu Y, et al. [Effect of luteal-phase gonadotropin-releasing hormone agonist administration on pregnancy outcome in IVF/ICSI cycles: a systematic review and Meta-analysis]. Zhonghua Fu Chan Ke Za Zhi. 2016. PMID: 27916070. doi:10.3760/cma.j.issn.0529-567X.2016.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。